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Pentagastrin Infusions in Patients with Parfic Disorder 
I. Symptoms and Cardiovascular Responses 
James L. Abelson and Randolph M. Nesse 
Cholecystokinin ( CCK) may mediate human anxiety and animal data suggest that cholecysto- 
kinin antagonists could provide an important advance in the treatment of anxiety disorders. The 
study of CCK receptor systems in psychiatric patients has, however, been severely limited by the 
lack of available probes. We utilized intravenous infusions of pentagastrin, a selective CCK-B 
receptor agonist, and studied behavioral and cardiovascular responses in lO patients with panic 
disorder and 10 normal controls. Pentagastrin produced substantial symptomatology, including 
anxiety, and increases in heart rate and blood pressure, in both patients and controls. Patients 
were more sensitive to the panicogenic effects of the pentagastrin. Panic attacks occurred in 70% 
of patients and 0% of controls. Patients" symptom responses were very similar to their "'typical" 
panic attacks and to symptoms produced by CCK, Pentagastrin provides a readily available 
alternative to CCK~ for studying the CCK receptor system and exploring its involvement in 
human anxiety. 
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Intradnetion__ 
A growing body of basic research suggests that cholecysto- 
kinin (CCK) may mediate anxiety. CCK agonists, such as 
CCK, and pentagastdn, are anxiogenic in both animals and 
humans (Abelson and Nesse 1990; Bradwejn et al 1991; 
Singh et al 1991) and CCK receptor antagonists can block 
anxiety (Bradwejn et al 1993; Singh et al 1991). Preclinical 
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studies using recently developed, highly selective CCK-B 
receptor antagonists suggest that these drugs have potential 
utility in the treatment of anxiety disorders and drug abuse 
(Costall et al 1991; Hughes et al 1991) and may provide 
anxiolytic activity without significant sedation, tolerance, 
or withdrawal on abrupt discontinuation (Costall et al 
1991). These drugs may also provide critical new tools for 
studying CCK receptor systems in humans. 
Despite advances in our basic understanding of CCK 
systems and the therapeutic potential of new antagonists, 
there have been few detailed human studies of the behav- 
ioral, clinical, physiological, and neuroendocdne effects of 
available CCK ~,gonists. The largest body of work to date, 
by Bradwejn and colleagues, demonstrates that CCK~ can 
induce panic attacks and that panic patients are more sensi- 
tive to this panicogenic effect than normal subjects (Brad- 
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wejn et al 1991). This Montreal group has provided exten- 
sive data to support the use of CCK4 as a laborato~ model of 
panic (Bradwejn et al 1990, 1991, 1992a, 1992b, 1993). To 
date, however, no replications from other laboratories have 
been published, and few neuroendocrine studies have been 
done. Wider study may be inhibited by limited access to 
CCl~ for human use in many countries, including the 
United States. 
Pentagastrin is a 5-amino acid synthetic analogue of gas- 
trin developed for diagnostic evaluation of gastri~ acid se- 
cretory function (Baron 1972). It contains CCK~ as its car- 
boxyl terminal sequence. Gastrin and CCK are closely 
related peptide families and both pharmacological (Lotti 
and Chang 1989) and cloning data (Pisegna et al 1992) 
suggest that the gastrin and CCK-B receptors are identical. 
Two CCK receptors have been identified (Saito et al 1980) 
and were initially dichotomized as central (CCK B or brain) 
and peripheral (CCK-A or alimentary) types. Though recent 
work suggests that both receptors are found in the brain 
(Woodruff and Hughes 1991), the CCK-B subtype predom- 
inates and is widely distributed centrally in all mammals 
studied (Woodruff and Hughes 1991). Gastxin-like immu- 
noreactivity was first demonstrated in the brain in 1975 
(Vanderhaeghen et al 1975) and is now known to be com- 
prised of CCK/gastrins of varying length molecular forms 
(Morley et al 1984; Sauter and Frick 1983). True gastdns 
(Rehfeld 1978a, 1978b), the CCK octapeptide (CCKs), and 
smaller CCK fragments (Morley et al 1984; Sauter and 
Frick 19.83) have all been isolated from the mammalian 
brain and have demonstrated differing affinities for CCK-A 
and B receptors. Both receptors have high affinity for sul- 
fated CCKs, whereas desulfated forms (including gastdn, 
pentagastrin, desulfated CCKs, and CCK~) are selective for 
the gastrin/CCK-B receptor (Hughes et al 1990). The tetra- 
peptide (Phe-Asp-Met-Trp) carboxyl terminal sequence 
shared by naturally occurring gastrins, pentagastd/~, and 
CCK~ appears to be the minimal structure necessary, for 
activity at gastrin/CCK-B receptors. CCK4 is the most se- 
lective CCK-B receptor agonist available for use in humans. 
Pentagastrin has slightly greater affinity and lower selectiv- 
ity for the CCK-B receptor than CCK~, but is still highly 
selective (700-fold selectivity for the CCK-B over CCK-A 
receptor) (Hughes et al 1990). It is the most selective CCK- 
B receptor agonist available in the United States. 
We began using pentagastrin infusions in 1988 to stimu- 
late vasoactive peptide release in patients with panic dis- 
order. Pentagastrin's ability to release such peptides (Ahl- 
man et al 1985; Oberg et al 1989; Vinik et al 1990) and the 
similarity of its "side effect" profile to the symptoms of a 
panic attack suggested it could contribute to the search for 
mechanisms of panic symptom production. Bi-adwejn's 
work has now confirmed that CCK-B agonists induce anxi- 
ety and panic (Bradwejn et al 1991 ), though data relevant to 
mechanisms remain SCant. Confirmation of Bradwejn's 
findings and the search for mechanisms would be greatly 
facilitated if the more readily available agonist, pentagas- 
trin, could be shown to produce effects similar to CCI~. 
This report presents behavioral and cardiovascular data 
from the first two phases of our pentagastrin studies of panic 
disorder patients and normal subjects. The data support the 
viability of pentagastdn as an alternative to CCK~ for the 
laboratory study of panic. Because ofour interest in mecha- 
nisms, neuroendocrine data was also collected and will be 
reported separately. Preliminary reports of some neuroen- 
docrine (Abelson et al 199 !) and behavioral data (Abeison 
and Nesse 1990) have already a p ~ ,  but included data 
from only 10 subjects who did not receive placebo control 
infusions. 
Methods ,and Materials 
Subjects 
All 20 subjects gave informed consent and were free of 
psychotropic medication for at least 2 weeks p~-ior to study. 
They were medically healthy as determined by history, 
physical examination, and screening laboratory tests. All 
subjects, including controls, were evaluated using a Struc- 
tured Clinical Interview for DSM-HI-R (Spitzer and Wil- 
liams 1986). The patients were recruited through newspaper 
advertisements and from routine referrals to our anxiety 
disorders program and were paid $100 for their participa- 
tion in the protocol. They all met DSM-HI-R criteria for 
panic disorder or panic disorder with agoraphobia. They did 
not meet criteria for current major depression or substance 
abuse (within the past 6 months) and did not have any 
history of primary depression or psychosis. Control subjects 
were age-matched and gender-matched to the patients and 
did not meet criteria for any Axis I disorder. All women had 
normal menstrual cycles and were studied within 10 days of 
onset of menses. Total medication exposure in the months 
prior to study was minimal. One control subject had a few 
doses of a nonsteroidal antiinflamatory drug during her 
period l0 days prior to study and another had a few puffs 
from an albuterol inhaler for seasonal allergies over a week 
prior to study. Only two patients had been on daily pharma- 
cological treatment for panic disorder (one was taking bu- 
spirone and another alprazolam), but both discontinued 
their medication over a month prior to study. A third patient 
had used occasional doses of lorazepam (2-3 times/week) 
up until 3 weeks prior to study. 
Desigl~ 
The study design was partially shaped by constraints im- 
posed by the neuroendocrine component. It was conducted 
in 2 phases in a clinical research center (CRC). In the first 
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phase five patients and five controls received a single infu- 
sion of pentagastrin in conjunction with frequent blood 
sampling to provide detailed data on hormonal response 
patterns. In phase two sampling frequency was reduced to 
allow addition of a placebo infusion session without ex- 
ceeding blood volume limits. An additional five patients 
and five controls were recruited and were admitted on two 
occasions a week apart, receiving a saline placebo infusion 
on visit one and pentagastrin on visit two (administered in a 
single-blind fashion). We administered the active substance 
second because panic patients are reactive to novel situa- 
tions and therefore stress-reactive endocrine measures were 
likely to be closer to baseline levels during the second visit. 
Phase two was identical to phase one except for the addition 
of the placebo infusion and the reduced blood sampling 
frequency. 
Subjects were told that the study focused on stress hor- 
mones, whose release was stimulated by pentagastrin. The 
side effect profile of pentagastrin was fully described orally 
and in the written consent form and subjects were explicitly 
informed that some of the side effects were similar to symp- 
toms commonly experienced in panic attacks. The consent 
form mentioned the possibility that a panic attack could 
occur during ",he study. When patients expressed apprehen- 
sion about having a panic attack in response to the infusion 
they were told that our intent was not to induce an attack but 
rather to examine hormonal responses to the drug. They 
were assured that any intense symptomatic responses to the 
drug would last only a few minutes and that the study 
psychiatrist would be at their side to supportively assist 
them through whatever symptoms and anxiety they might 
experience. Our goal was to provide adequate reassurance 
and support to minimize undue distress since our primary 
interests were pharmacological, neuroendocrine, and 
mechanistic. 
Control subjects were given verbal descriptions of DSM- 
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tempt to connect these descriptions to their own reports of 
real fear experiences. Sufficient details and discussion were 
provided to insure that control subjects could appropriately 
report whether they experienced a panic attack during the 
procedures. 
Procedures and ~easures 
3~bj~cts were admitted ~o the CRC the night prior to study 
and had no food from 10 PM until completion of the proto- 
col. They were awakened at ~:30 ~x~ and at $ ~ an indwel- 
ling heparin lock catheter was inserted into an antecu~itai 
vein. Baseline blood samples were drawn between $:30 and 
~:~9 ~vj. At 9 ~ d  pentagastrin (commercially available 
Peptavlon, TM Wyeth-Ayerst Laboratories, Philadelphia, 
PA) was infused into the heparin lock, in view of the patient, 
in less than 1 min, at a dosage of 0.6 ~g/kg, in a saline 
vehicle of less than 1 ml. Anxiety symptoms were ~ -  
toted using a version of the Acute P a ~  Inventory (API) 
(Dillon et al 1987), modified to include ~ ~ symp- 
toms as listed in DSM-IFI-R, with some of the c ~  
items listed separately (e.g., "nausea or ~ ~ "  
listed as 2 separate items). We aLto added six additi~al 
potential side effects of pentagastrin ( u n u ~  taste or n i l ,  
drowsiness, blurred vision, beada~he, ~ ,  irritability). 
The instrument has a total of 25 items. Subjects rated ~ 
own symptoms on a 4-point scale from 0 (no~ at all) to 3 
(severe). Subjects also gave a yes or no response to the 
question, "Did you, or are you now having a ~ i c  auack?" 
Symptom ratings obtained 30 min and 10 min before infu- 
sion were averaged to provide baseline levels. A~t iona l  
ratings were obtained at 5, 10, 20, 30, and 45 rain after 
infusion. The +5 min symptom ratings l~O~,,ided a measure 
of peak symptoms as all subjects experienced an acute 
symptom peak within the first few minutes after pentagas- 
trin infusion and were told to rate these symptoms at the +5 
min rating. When both of the subjects' arms were o c c u ~  
(due to blood pressure monitoring and blood drawing) 
symptom ratings were reported verbally to the study physi- 
cian for recording. The study physician was not blind to 
diagnosis. Patient responses to p e n t a g a s ~  were such ~ a 
physician blind would have been difficult to maintain had it 
been attempted. 
Heart rate (HR), systolic blood pressure (SBP), and dias- 
tolic ~ood pressure (DBP) were measured using an Air- 
Shields automated monitor. Recordings were obtained 30, 
10, and 2 min prior to infusion, approximately 2, 5, 7, and I0 
min after infusion, and every 5 min thereafter for 60 min. 
DataAnalysis 
We first analyzed responses from the pentagastrin infusion 
visit for all subjects using three-way, repeated measures 
analyses of variance (ANOVA) with phase and diagnosis 
t'nnti,~nt v,~r~:u~ enntrnl)  as berN!__ een ~m'oup variables and t ime ~ . l . ~ - ~  
as a within group variable. The effect of phase was exam- 
ined to determir, e if prior experience w~.th the infusion pro- 
cedure (placebo session) air d responds to pentagastrin 
for phase two subjects. The ume-by-diagnosis interaction 
reflected patient/control group differences in responsivity 
to pentagastrin. A second set of ANOVAs examined re- 
sponses to pentagastrin and placebo in phase two subjects 
only. In these analyses diagnosis was the between group 
variable; drug (placebo/pentagastrin) and time were within 
group variables. The drug-by-time-by-diagnosis interaction 
in these analyses rejects the degree to which patients and 
controls responded differently to the t~o conditions (pla- 
cebo versus pentagastrin) and thus provides the most strin- 
gent test of whether patients were more sensitive to specific 
pharmacological effects of the drug. 
To analyze overall symptom responses to pentagastrin, 
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we applied the just-described ANOVAs to three dependent 
measures derived from the symptom rating scales: (1) num- 
ber of symptoms present (those rated at least mild); (2) total 
symptom intensity (sum of individual symptom ratings); 
and (3) the score on the anxiety item ("worried, nervous, 
anxious") of the modified APl. The time factor in the 
ANOVAs for symptom measures involved ratings obtained 
prior to infusion (mean baseline) and 5 min after infusion 
(peak symptoms). 
To analyze cardiovascular responses to pentagastrin, we 
applied the above ANOVAs separately to SBP, DBP, and 
HR. Because of some missed samples and variability in 
individual measures, cardiovascular data was averaged to 
obtain four time points for analysis: mean baseline, imme- 
diate postinfusion (a single measurement obtained 1 to 3 
min after infusion), 5 to 10 min mean, 10 to 30 min mean, 
and 45 to 60 min mean. 
Additional analyses (described in Results section) were 
used to assess the duration of the symptom responses to 
pentagastfin, to compare patients and controls in frequency 
of pentagastrin-induced panic attacks, to compare penta- 
gastfin-induced attacks to "typical" panic attacks, and to 
compare pentagastfin-induced attacks to CCK~-induced 
attacks. 
R e s u l t s  
One control subject in phase one had a resting norepineph- 
fine level of over 1000 pg/ml, suggesting a neuroendocdne 
abnormality, and he was dropped from all analyses. The 
final sample consisted of 9 control subjects (mean age = 
26.2 _+ 4.8 years; one man) and 10 panic patients (mean age 
= 28.3 _+ 8.3 years; 2 men). The patient and control groups 
did not differ significantly in age or body weight. The pa- 
tients had an average age of panic disorder onset of 25.9 
(--.7.7) years. Patients in phase two averaged 13.4 (_+5.5) 
full-symptom panic attacks in the month prior to study 
screening (comparable data not available for phase one 
patients). Subjects in phase one and phase two did not differ 
in mean body weight (t = 1.0,p = 0.32); but subjects in phase 
one tended to be slightly older than those in phase two (30.3 
-+ 8.4 years versus 24.6 +_ 3.4 years, t = 2.0, p = 0.06). 
Patient groups in the two phases did not differ in age of onset 
or duration of illness. 
Panic Attacks 
Seven of 10 panic patients subjectively reported having a 
panic attack within the first 5 rain after pentagastrin infu- 
sion, compared to only one of nine control subjects. None of 
the five patients and five controls who received a placebo 
infusion reported a panic attack following the placebo. Ap- 
plying the criteria for a pharmacologically induced panic 
attack originally proposed by Klein's group (Dillon et al 
1987), quantified by requiring that the symptom profile 
meet DSM-III-R's four symptom criterion and that there be 
at least a two point increase from baseline in the subject's 
rating of anxiety, pentagastrin induced panic attacks in 7 of 
10 patients and zero of nine controls (Fisher's exact test, 
p = 0.003). 
Overall Symptom Responses 
The initial three-way ANOVA (phase-by-diagnosis-by- 
time) showed no significant main effects or interactions 
involving phase for any of the three symptom measures, 
indicating that whether patients were naive to the infusion 
situation when they received pentagastrin (phase 1) or had 
prior experience with it (phase 2) had no effect on symptom 
responses. Combined data for the two phases are summar- 
ized in Figure 1. The main effect of diagnosis was signifi- 
cant in all three ANOVAs. Patients, relative to controls, 
endorsed a greater number of symptoms [F(I, ! 5) = ! 2.2, p = 
0.003], experienced greater symptom intensity IF(I,15) 
= 14.9, p = 0.002 ], and rated their anxiety higher [F(1,15) = 
10A, p = 0.006] throughout the pentagastrin infusion proce- 
dure. The main effect of time was also significant in all three 
ANOVAs, due to the substantial rise in number of symp- 
toms IF(I, 15) = 104.5, p = 0.0001 ], total symptom intensity 
IF(I,15) = 98.4, p = 0.00011, and anxiety [F(I,15) = 36.7, 
p = 0.0001 ] produced in both groups by pentagastrin infu- 
sion. The time-by-diagnosis interaction was significant for 
total symptom intensity [F(I,15) = 7.3, p = 0.016] and 
anxiety ratings IF( 1, ! 5) = 5.6, p = 0.032] but not for number 
of symptoms [F(I, 15) = 1.9, p = 0.187]. These analyses and 
Figure 1 reveal that: (1) panic patients endorsed greater 
symptomatology on all measures at all time points; (2) 
patients also responded to pentagasuin with greater rises in 
anxiety and symptom intensity than did controls (reflected 
in the graphs in differences in slope); but (3) the rise in 
number of symptoms in response to the infusion did not 
differ significa_n.fiy betw~n groups. 
A second set of ANOVAs was necessary because the act 
of being infused (infusions were given in view of the sub- 
jects) could elicit "placebo" responses that should be re- 
moved to see true pharmacological effects of active drug 
(placebo response data is included in Figure l). Differential 
responsivity to pentagastrin versus placebo is reflected in 
interaction effects involving drug in the three-way (drug- 
by-time-by-diagnosis) ANOVAs based on the placebo- 
controlled phase two data. Drug-by-time interactions were 
significant for number of symptoms IF(l,8) = 30.9, p = 
0.0005] and total symptom intensity IF(l,8) = 36.0, p = 
0.0003], but not for anxiety rating IF(l,8) = 0.8, p = 0.41], 
indicating that pentagastrin produced substantially greater 
rises in symptom number and intensity than did placebo; but 
the anxiety response to pentagastdn was not significantly 
greater than the anxiety response to the act of being hffused. 
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Figure 1. Mean number of symptoms, total symptom intensity, 
and anxiety ratings at baseline and following infusion (error bars 
show SEMs). The solid lines (closed symbols) show responses to 
pentagastrin in the total subject groups (10 panic patients and 9 
controls). The dotted lines (open symbols) show responses to 
placebo infusions in the subgroups studied in phase 2 (5 patients 
and 5 controls). 
None of the six interaction effects involving both drug and 
diagnosis reached significance (drug-by-diagnosis; p > 
0.50 for number of symptoms ana p ~- 0.13 for total symp- 
tom intensity and anxiety rating; drug-by-t~me-by diagno- 
sis: p > 0.80 for number of symptoms and ~mxiety rating, 
p > 0.30 for total symptom intensity). These results suggest 
that patient versus control differences in symptom and anxi- 
ety responses (seen in the initial analyses) reflect differen- 
tial responsivity to receiving an infusion and not differential 
responsivity to the pharmacological content of the infusion. 
Two additional statistical tests support this ~ | ~ .  
First. patients showed significantly greater symptom re- 
sponses to the placebo infusion ~ did controls. A~ys~s  
of placebo day change from baseline scores (postinfusion 
symptom ratings minus baseline ~ g s )  ~monstra~d ~ 
patients had greater increases in number of symptoms |~8) 
~- 3.8, p ~-0.005] and total symptom intensity [~8)-- 3.8, p-~ 
0.008], and tended to show a greater increase in anxiety 
rating [KS) ~- 2.0, p -- 0.08]. We also subtracted t ~  ~acebo 
day change from baseline scores from the p e n t a g ~  day 
change from baseline scores for number of ~ p t o m s ,  total 
symptom intensity, and anxiety rating. These "d i f f e r e~  of 
difference" scores reflect the r e s ~  to pentagastrin over 
and above the response to placebo. Using these scores, 
patients and controls did not differ for any of the three 
dependent measures. In fact, control means were greater 
than patient means for increases in number of symptoms 
[controls -- 9. I ~_ 5.0, patients = 8.3 - 4.9, t(8) = 0.3, p -- 
0.80] and anxiety ratings [controls -- 0.5, patients--0.3, ~8) 
= 0.2, p -- 0.83]. For total symptom intensity the control 
mean was i 5.5 ± 9.3 and the patient ~ was 21.9 ~- 10.4 
[t(8)-- 1.0,p--0.33]. 
To examine the time course of the symptom responses to 
pentagastrin, we compared symptom levels at each postin- 
fusion time point to mean baseline symptoms (using paired 
t-tests). There is some imprecision in this approach, as we 
did not collect continuous reports of symptoms as they 
occurred and the first "postpeak" ratings were. not collected 
un61 10 min after the infusion. Our subjects reported, how- 
ever, that intense symptomatology lasted for 1 to 4 min. 
Symptom reports returned to baseline rapidly for control 
subjects and more slowly for patients. The analyses support 
these reports. For all subjects the immediate postinfusion 
symptom levels were substantially and highly si~ficantly 
elevated above baseline (p < 0.005 for number of symp- 
toms, tota! symptom intensity, and anxiety rating). For con- 
t~rd e . h i o P t g  rill t h r ~  g v m n t n m  measures h_ad retu,-qed to 
u , . . , ~  o ~ , ~ . . . j ~ , ~ . , . o ,  . ' . / - - - r  - - 
baseline levels by 10 min after the infusion (p > 0.17 for 
each measure). Patients had returned to baseline levels in 
anxiety ratings by 10 min after the infusion (p > 0.80), but 
were still reporting more symptoms and a greater total 
symptom intensity than at baseline (p < 0.05 for both). By 
30 rain after infusion symptom and anxiety levels for both 
groups were nearly identical to baseline levels. It appears 
then that patients had a more sustainext symptom (but not 
anxiety) response to pentagastrin than did controls. The 
analyses produced identical results when performed on the 
smaller group of phase two subjects alone. Phase two pa- 
tients also had mild, sustained symptom responses to the 
placebo infusion, however, and as with other analyses, 
when placebo day symptoms were subtracted from penta- 
gastdn day symptoms, the patient-coatrol differences dis- 
appeared, that is, both patients and controls had signifi- 
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Table I. Intensity of Panic Symptoms Induced by Pentagastrin and Characteristic of Patients" "Typical" Attacks" 
Pentagastrin Typical attack Patients versus Pentagasuin versus  
controls typical 
patients controls (patients only) 
( n =  I0) ( n = 9 )  ( n = 9 )  t p ! p 
Flushed/chilled 2.5 -+ 0.3 
Short of breath 2.4 + 0.3 
Anxious/worried 2.2 - 0.4 
Heart racing/pounding 2. I _.T. 0.3 
Nausea 2.0 "*" 0,4 
Sweating 2.0 - 0.4 
Dizzy/unsteady 2.0 _ 0.3 
Faint 1.9 - 0.4 
Chest pain/discomfort i.8 _ 0.4 
Upset stomach !.5 _ 0.4 
Fear of losing control ! .2 -+ 0.4 
Shaking/trembling 1.2 _ 0.3 
Fear of dying 1.2 _ 0.4 
Choking !.0 ± 0.4 
Numbness/tingling 0.6 - 0.2 
Fear ofgoingcrazy 0.5 ± 0.2 
Numherofsymptoms 12.5 _ 0.9 
Total symptom intensity 28.1 ± 2.9 
2.1 - 0.2 2.0 _ 0.3 !,1 0.27 
0.8 - 0.3 !.8 _ 0.2 3.6 0.002 
0.7 ± 0.2 2.7 ± 0.2 3,7 0.002 
!.2 "*" 0.4 2.4 "*- 0.2 1.7 0.10 
2.1 ± 0.3 0.8 -* 0.4 0.2 0.82 
0.9 ~- 0.4 1.4 ± 0.4 2,. ! 0.05 
0.7 - 0.3 i.9 - 0.4 3.0 0.008 
0.3 - 0.2 1.8 ~ 0.4 3A 0.003 
1.0 ± 0.4 I. 1 _+ 0.4 !.5 0.14 
1.3 ± 0.4 1.3 ~- 0.4 0.3 0.77 
0.4 _ 0.2 i.9 +_ 0.4 !.6 0.12 
0.3 "*- 0.2 !.6 ± 0.3 2.3 0.04 
0.0 _ 0.0 ! .6 _ 0.5 2.6 0 . 0 2  
0.7 _ 0.4 0.4 +- 0.3 06 0.57 
I. I ~ 0.4 1.3 _ 0,5 I, I 0.23 
0.0 ± 0.0 1. i ± 0.5 2. i 0.05 
8.2 - 1,2 12.4 _+ 0:6 2.8 0.01 
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i .2 0.28 
0 .2  0 . 8 5  
0 .2  0 . 8 3  
-Values ar~ mean _ SEM. Symptom intensity was rated on a 0 to 3 scale. 
cantly elevated symptom levels only immediately following 
the infusion (p < 0.05 for both groups for number of  symp- 
toms and total symptom intensity) and had returned to base- 
line by 10 min later (p > 0.28 in all analyses). 
Comparison to Typical Attacks 
Prior to entry into the experiment each patient (except l )  
used our version of  the API to provide symptom ratings for a 
recent "typical" panic attack, allowing us to compare pen- 
tagastrin-induced symptoms to the patients'  usual attacks. 
We used paired t-tests to compare ratings of  each symptom 
and Kendall 's  tau (Hayes 1981) to compare the symptom 
profiles (i.e., rank ordering of  symptoms). For. these and 
s ~ , ~ - n t  analy~,e~ we used only those symptoms from our 
version of  the API that are also included in the DSM-IlI -R 
list of  panic attack symptoms. Mean ratings and t-test results 
are presented in Table I. Ratings differed significantly for 
only two symptoms, "flushed/chilled" and "nausea,"  both 
common pentagastrin side-effects. The number of  symp- 
toms and total symptom intensity reported following penta- 
gastfin were nearly identical to those experienced with typi- 
cal panic attacks (see Table 1 ). The symptom profiles were 
quite similar, tau = 0.47,p < 0.01. 
Comparison to CCK-4 Responses 
Our protocol for infusing pentagastxin is essentially identi- 
cal to that used by Bradwejn et al (1991) for their CCK4 
infusions. Our rating scale differed in that it did not include a 
rating of  4 (very severe), and there were minor differences in 
the wording and breakdown of  the compounded DSM-IH-R 
symptoms. To  allow a direct comparison of  symptom re- 
sponses the Bradwejn group recalculated their means on a 0 
to 3 scale, with their ratings of  3 and 4 lumped together as 
ratings of  3 (J. Bradwejn, personal communicat ion,  1993). 
Recalculations were done for two cohorts of  panic patients 
(Bradwejn et ai 1991, 1992b) and one cohort of  controls 
(Bradwejn et al 1991) who received 25 Ixg of  C C I ~  and for 
one cohort each of  patients and controls who received 50 Itg 
of  C C I ~  (Bradwejn et al 1991). We could then compare 
pentagastrin-induced symptoms to CCK,- induced symp- 
toms, using paired t-tests to compare ratings of  each symp- 
tom and Kendal l ' s  tau (Hayes 1981) to compare the symp- 
tom profiles. G_raphic compari.~on c~f pati~nt~' ~vmntt~m . . . . . . . . . . . . . . . . .  ~ j ,  . . . ~ . . ~ v . ~ .  
profiles (pentagastrin versus 25 t tg CCK~) is presented in 
Figure 2. (graphic comparison with 50 p,g CCK4 available 
upon request). 
Patients receiving 25 p,g of  CCK4 did not differ from 
those receiving pentagastrin in their mean rating of  any of  
16 panic attack symptoms for either cohort  It(19) < 1.71, 
p > 0.10 in all 32 comparisons].  Control subjects receiving 
25 p,g of  CCK4 also did not differ from those receiving 
pentagastrin on any panic symptom rating [t(22) < 1.64, 
p > 0.10 for all 16 symptoms].  Panic patients receiving 50 
~g  of  CCK, compared to patients receiving pentagastrin, 
reported significantly more numbness [t(19) = 3.68, p < 
0.05] and tended to report less abdominal  distress It(19) = 
1.81, p < 0.10], but did not differ on any other symptom 
[t(19) < 1.64,p > 0.10]. Controls receiving 50 p,g of  CCK, 
compared to controls receiving pentagastrin, reported sig- 
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Figure 2. Mean ratings of symptom intensity (0 = none, 3 = se- 
vere) for the panic attack symptoms for which we had sufficiently 
comparable data to allow direct comparisions of pentagastrin-in- 
duced symptoms (bars) to CCK~-induced symptoms (squares). 
The CCK~ data are recalculated (Bradwejn, personal communica- 
tion, 1993) from a cohort of panic patients given 25 p.g of CCK, 
_ - - ,  : - : . : - , , . .  fibedby n . -a  . . . .  ; . . . .  l / I O O l ~  T h ~ t ~ A r , ~ c A i d  ] l i f t  I i l l l . l i l l l ~  d e s c  I J | a u w ~ j = l  ~ , t  a =  ~. t . ~ t  = ! -  , ~  . . . .  
not produce different ratings for any syumptom, even at a trend 
level (p < 0.10). Symptoms are arranged in descending order of 
intensity as experienced following pentagastrin to provide a 
cleaner graphical presentation. 
nificantly more shortness of breath [t(22) = 2.41, p < 0.05] 
and tended to report more unsteadiness and fai::-'ess t,~,-,-,t'~'~'~ 
= 1.91 and 2.03, respectively, p < 0.10 for both]. The rank 
orders of CCF~-elicited symptoms as determined by pa- 
tients' mean ratings were significantly related to the profile 
of pentagastrin-elicited symptoms for all three CCK~ patient 
cohorts (tau = 0.50 and 0.57, p < 0.008 for the two 25 lxg 
cohorts; tau = 0.52,p < 0.008 for the 50 p.g cohort). 
We also compared pentagastrin and CCK, in their ability 
to differentiate patients from control subjects, in individual 
symptom responses and in total number and intensity of 
symptoms e x p e r i e ~ .  The published examination of pa- 
tient-control differences in i ~ v i d u a l  symptom ~ fol- 
lowing CCK, appeared in a dose response study that util~ z~.d 
25 Ixg and 50 Ixg infusions of CCI~ (Bradwejn et al 1~1) .  
Group differences (patient versus control) were repor'axl for 
the overall effect of  CCK~, regardless of ~ ( ~  ~ ~ -  
dose interactions were significant). ~ ~ n'~,ans, 
SEMs, and statistical tests a ~  in Table 1. Of t ~  16 
symptoms that are comparable across studies, patients ~ 
controls differed significantly in their ratings of six follow- 
ing CCI~  infusion and in their ~ n g s  of seven following 
pentagastrin infusion. In both cases patients and controls 
differed in the number of symptoms produced and the t ~  
symptomintensity. For all variables the patients were more 
symptomatic than controls. The items that differentiated 
patient and control groups with ~ CCK, and pentagastrin 
were shortness of breath, shaking, fear of going crazy, and 
anxiety. 
Cardiovascular Responses 
As in the analyses of symptoms, t ~  initial three-way 
ANOVAs for SBP .and DBP found no significant effects 
involving phase (see Figure 3 for data collapsed across 
phase). For both SBP and DBP the main effect of time was 
significant [F(4,60) = 9.7,p = 0.0001 and F(4,60) = 4.1, p = 
0.005, respectively], and the diagnosis-by-tin:¢ interactions 
approached significance [F(4,60) = 2.3, p = 0.065 and 
F(4,60) = 2.4, p = 0.056, respectively]. Unpaired t-tests 
indicated that the trend toward patient-control differences 
in SBP response to pentagastrin was due to elevated SBP in 
patients 5 to 10 min [t(17) = 2.7, p = 0.02] and I0 to 3~ rnin 
after the infusion [t(l 7) = 2.2, p = 0.04]. For DBP the group 
differences appeared only at 5 to 10 rain after infusion [t(l 7) 
= 2.7, p = 0.016]. The groups did not differ significantly in 
SBP or DBP at baseline, immediately after the infusion, or 
45 to 60 min later, although there was a trend for patients to 
have elevated DBP at baseline [t(17) .-: 1.9, p = 0.068]. 
The initial three-way ANOVA for HR showed a signifi- 
cant effect of time [F(4,60) = 31.3, p = 0.0001 ]. The main 
effects of diagnosis and phase were not significant, but all 
three interactions involving phase were significant [phase- 
by-diagnosis: F(I,15) = 7.9, p = 0.013; phaze-by-time: 
F(4,60) -- 4.5, p = 0._00_3; and phase-by-diagnosis-by-time: 
F(4,60) = 2.7, p = 0.0381. Examination of graphs showed 
these interaction effects to be due to lower HRs immediately 
following the infusion in panic patients in phase 1. Review 
of data sheets revealed that substantially fewer subjects 
from this group had recordings of heart rate obtained within 
the first 2 min following the infusion. This failure was a 
consequence of the highly symptomatic responses of pa- 
tients, our lack of preparation for the strength of these re- 
sponses early in phase 1, and a resultant failure to properly 
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Figure 3, Cardiovascular responses (means - SEM) to pentagas- 
trin infusion in panic patients (n = 10) and normal controls (n = 9). 
The baseline measure is the mean of recordings made between 30 
and 2 rain before infusion; T i represents a single measure recorded 
between ! and 3 rain after infusion; "1"2 to T4 represent the means 
of recordings made 5 to ! 0 rain, I 0 to 30 rain, and 45 to 60 rain after 
infusion, respectively. Asterisks mark time points at which pa- 
tients and controls differed (p < 0.05). 
trigger the automatic monitor to begin recording immedi- 
ately after the infusion. A similar systematic failure to ob- 
tain immediate post-infusion HR measures did not occur in 
the control group, and the HR response curves for controls 
were identical for the two phases. The HR data is included in 
Figure 3, collapsed across phase. The peak HR for patients 
(time TI)  is probably artificially reduced by the above 
problem. 
As with symptom data, follow-up ANOVAs were applied 
to phase two data to control for placebo effects. Significant 
drug-by-time interactions for HR [F(4,32) -- 20.1, 
p = 0.0001 ] and SBP [F(4,32) = 4.5, p = 0.006] indicated that 
pentagastrin produced greater rises in HR and SBP than did 
the act of being infused. The drug-by-time interaction for 
DBP did not reach significance [F(4,32) = 2. l ,p  = 0.11 !; b~zt 
the DBP response to pentagastrin appeared greater and 
more prolonged; and the main effect of drag IF(I,8) = 5.3, 
p = 0.051 ] and a significantly greater peak DBP response to 
pentagastrin than placebo It(9) = 4.1, p = 0.003] support a 
differential effect. There was a significant main effect of 
diagnosis only for HR IF(I,8) = 9.5,p = 0.015]. No interac- 
tions involving diagnosis approached significance (F < 
2.34,p > 0.16 or all two-way interactions; F < 0.(~,p > 0.65 
for all three-way interactions) for any of the three cardio- 
vascular measures, suggesting no differential sensitivity 
to the active drug when controlled for placebo response 
differences. 
In summary, the analyses suggest that HR, SBP, and DBP 
all increase in response to pentagastrin in patients and con- 
trois. The two groups do not appear to differ in their cardio- 
vascular responses to the drug, but panic patients tended to 
have higher HRs throughout the procedures. 
Correlational analysis revealed a significant relationship 
between anxiety levels following pentagastrin infusion and 
baseline HR (r = +0.7, p = 0.001). Furthermore, those pa- 
tients who had panic attacks in response to pentagastrin had 
higher baseline HRs than those who did not panic It(8) = 3.8, 
p=0.006]. 
Discussion 
Pentagastrin and CCK, 
Our findings demonstrate that pentagastrin produces symp- 
tom and cardiovascular responses similar to those produced 
by CCK, and thus provides a CCK-B receptor agonist 
model of panic that is available to researchers in the United 
States. There are inherent limitations in comparing data 
collected at different sites and using slightly different para- 
digms and instruments; but the similarities between penta- 
gastrin and CCK, in symptom ratings, symptom profiles, 
and ability to differentiate panic patients from controls are 
striking. The time courses of symptom responses are also 
remarkably similar. Our impression tho?., acute responses to 
pentagastrin lasted 1 to 4 min and our analyses, which 
indicate a return to baseline levels within 5 to 10 min for 
controls and within 20 to 30 min for patients, are in good 
accord with the durations reported for CCK, (acute re- 
sponses lasted 2 rain, with return to baseline in 10 rain with 
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25 ttg and 20 min with 50 ttg) (Bradwejn et al 1991, 1992a). 
Though definitive conclusions cannot be reached without 
direct comparisons in a single laboratory, we believe the 
similarities are striking enough to support the viability of 
pentagastrin as an alternative to CCK, for the study of 
CCK-B receptor systems in human anxiety research. 
We found some differences in the symptoms produced by 
the two agents and the frequency of panic attacks reported in 
response to CCK, is greater than we found for pentagastrin. 
Dose effects may he relevant as response to CCK, is dose 
dependent (Bradwejn et al 1992a). Whether this dose- 
response relationship is a function of CCK-B receptor occu- 
pancy is not known. It is therefore difficult to predict 
whether pentagastrin, with its slightly greater affinity for the 
CCK-B receptor but lower selectivity for the CCK-B over 
the CCK-A receptor, should be more or less potent in pro- 
ducing symptoms. Our average dose of pentagastrin was 
41.5 t~g. This dose produced a level of symptomatology that 
appeared to fall between the levels produced by 25 ttg and 
50 ttg of CCK,. It shared more similarities with the lower 
dose in symptom profile and individual symptom intensity 
ratings but was more similar to the higher dose in duration of 
symptoms. The precise role of specific receptor interactions 
in CCK symptom induction remains unclear, but variations 
in receptor affinity and selectivity may have contributed to 
the minor response differences between pentagastrin and 
CCK,. 
Sampling error also likely accounts for some of the dif- 
ferences between drugs, as even within Bradwejn's labora- 
tory and using identical doses of CCK4, different samples of 
panic patients produced somewhat differing symptom pro- 
files (Bradwejn et al 1991; 1992b). Nonspecific aspects of 
the experimental setting and patient state (Cowley and 
Arana 1990) may also play a role, especially in the differ- 
ence in frequency of panic attacks. Cognitive set can alter 
the panicogenic properties of provocative agents (Cowley 
and Arana i990) a~d it is very possible that differences 
between laboratories, personnel, and study goals created 
different patient attitudes and expectancies at the two sites 
(see below). 
Mechanisms of CCK/Pentagastrin-lnduced Panic 
There is growing evidence that cognitive factors can medi- 
ate or modulate pharmacologically induced panic. Behav- 
ioral and cognitive manipulations which provide patients 
with a greater sense of control over provocative agents and 
that help them correctly attribute physical symptoms to 
known, short-lived, and safe effects of the agent can sub- 
stantially reduce the frequency of panic attacks in labora- 
tory models (Clark et al 1991; Rapee et al 1986; Sanderson 
et al 1989). Some have interpreted this data as suggesting 
that the mechanism of laboratory-induced panic involves 
catastrophic misinterpretation of somatic cues produced by 
provocative agents (Clark et al 1991). We did nat actively 
engage in anxiety-reducing cognitive ~ p u l a t i o n s  in this 
study; but because we were exploring a neuroendocrine 
probe rather than trying to develop a labor'~ory model of 
panic, we were not reluctant to offer ~ patients e ~  
support, reassurance, and comments ~ might help ~ 
avoid catastrophic misinterpretations of expectable ~ 
sbort-lived drag effects. We in fact offered c o n s i ~ l e  
support to those subjects whose fear of drug-induced panic 
produced reluctance to participate in the study (see Meth- 
otis). If cognitive factors can modulate drug-induced panic 
then differences in recruitment procedures and preparation 
of subjects for study could well have contributed to the 
difference in panic rates r e ~  for pentagastrin and 
CCIL. The fact that 41.5 I~g of pentagastrin produced 
slightly higher ratings than 25 ttg of CCK~ on 9 of 12 
physical symptoms but slightly lower ratings on three of the 
four fear/anxiety symptoms (see Figure 2), while producing 
very similar overall symptom profiles, is consistent with the 
possibility that cognitive factors were modulating fear/anx- 
iety responses to t,~ two agonists. 
Alternatively, CCK agonists may produce anxiety di- 
rectly through a highly specific receptor interaction within 
the brain; and CCFL may be sfightly more active at the 
relevant receptor site than pentagastrin. If so, enhanced 
sensitivity of that receptor in panic patients could then ex- 
plain patient-control differences in symptom/anxiety re- 
sponses to either drug. The lack of patient-control differ- 
ences in neuroendocrine responses to pentagastrirt (Ahelson 
et al 1994) argues against differences in receptor sensitivity. 
Other mechanisms of panic induction are capable of ex- 
plaining patient-control differences in response to CCK 
agnnism and both the similarities and differences between 
CCK~ and pentagastrin. All proposed mechanisms remain 
purely speculative at this point, however, as the data is not 
yet strong enough to convincingly support any single hy- 
pothesis. 
Though we did not design our study to specifically differ- 
entiate "cognitive" versus "pharmacological" mechanisms 
of panic induction, the consequences of correcting our sub- 
jects' responses to pentagastrin for their responses to the 
placebo infusion does support the hypothesis that nonphar- 
macological factors play a role in the anxiogenic activity of 
CCK agonism. Our initial analyses supported prior reports 
that panic patients, compared to controls, have enhanced 
symptom responses to CCK-B receptor agonists. In an ef- 
fort to strengthen the argument that group differences re- 
flect differences in pharmacological sensitivity to the pro- 
vocative agent, we conducted additional analyses that 
controlled for nonspecific aspects of subjects' responses to 
the act of being infused. Because panic patients were also 
more symptomatically responsive to the placebo infusion, 
however, patient-control differences in symptom number, 
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symptom intensity, and anxiety ratings were substantially 
attenuated in the placebo-controlled analyses, though 
strong responses to pentagastrin remained. The initial group 
differences may therefore have been due to differing re- 
sponsivity to nonspecific aspects of the infusion paradigm 
rather than to differing sensitivity to the active agent itself. 
The strength of this conclusion is weakened by two impor- 
tant caveats. One, it is possible that by statistically control- 
ling for responses to placebo we were actually overly con- 
servative as some of the placebo response may have been 
due to novelty effects (the placebo infusion was always 
given first and was therefore each subject's first experience 
with the act of being infused) that were no longer present 
when pentagastrin was given. Two, placebo-controlled 
analyses had very smali sample sizes, low power to detect 
significant differences, and high risk of a Type II error. 
Replication with a larger sample and better control of nov- 
elty effects is clearly needed. Patients did have greater 
symptom responses to the placebo infusion than did con- 
trols, however, and the significance of this difference de- 
spite the low power of the analysis may suggest that it is a 
fairly robust finding. If confirmed, it strongly suggests that 
efforts to control nonspecific factors in panic-provocation 
models must be intensified. Hypersensitivity to nonphar- 
macological aspects of challenge paradigms will make 
demonstration of true pharmacological sensitivities in panic 
patients substantially more difficult. 
Cardiovascular Responses 
Pentagastrin produced clear-cut, rapid, and substantial in- 
creases in heart rate and blood pressure. The heart rate 
response is likely even larger than we observed since our 
first recording was 2 rain after infusion and rates recorded at 
3 rain postinfusion were already substantially reduced com- 
pared to the 2-rain recordings. This impression is supported 
by Brandwejn's data (Bradwejn et al 1992a), which show 
somewhat larger heart rate responses than seen in our data, 
based on multiple recordings made within the first 2 min 
after infusion. More detailed comparison of cardiovascular 
responses between studies cannot be made because of the 
differences in time of measurement. The mechanism of this 
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